Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07TSV
|
|||
| Drug Name |
Atorvastatin
|
|||
| Synonyms |
atorvastatin; 134523-00-5; Cardyl; Xavator; Tozalip; Lipitor; Torvast; Sotis; ATORVASTATIN CALCIUM; Atorvastatin [INN:BAN]; 110862-48-1; UNII-A0JWA85V8F; CCRIS 7159; C33H35FN2O5; HSDB 7039; CI 981; Lipitor (TN); CHEMBL1487; A0JWA85V8F; CHEBI:39548; (betaR,deltaR)-2-(p-Fluorophenyl)-b; Atorvastatin
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperlipidemia [ICD-11: 5C80.Z] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 2 | [2] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C33H35FN2O5
|
|||
| Canonical SMILES |
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
|
|||
| InChI |
1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
|
|||
| InChIKey |
XUKUURHRXDUEBC-KAYWLYCHSA-N
|
|||
| CAS Number |
CAS 134523-00-5
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:39548
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [3] | |||
| Metabolic Effect | Increase activity | |||
| Description | Atorvastatin can be metabolized by gut microbiota, which results in the increase of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway) | Target Info | Inhibitor | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 205945. | |||
| REF 2 | ClinicalTrials.gov (NCT04380402) Atorvastatin in COVID-19. U.S. National Institutes of Health. | |||
| REF 3 | Gut Microbiome and Response to Cardiovascular Drugs. Circ Genom Precis Med. 2019 Sep;12(9):421-429. | |||
| REF 4 | Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020 Apr 29. pii: pvaa042. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.